Molina Healthcare, Inc.âs MOH
fourth-quarter 2018 adjusted earnings of $3.88 per share surpassed
the Zacks Consensus Estimate of $1.52 by a whopping 155.3%. This
upside was driven by higher premium revenues as well as decreasing
expenses. The bottom line also reversed the year-ago periodâs loss
of 34 cents.
For the quarter under review, total revenues came in at $4.6
billion, beating the Zacks Consensus Estimate by 1.8%. However, the
top line declined 5.7% year over year, mainly due to lower premium
and service revenues.
Quarterly Operational Update
The companyâs net income totaled $201 million against its
year-earlier period's loss of $262 million.
Total operating expenses declined about 16.8% year over year to
$4.3 billion. This improvement was attributable to lower medical
care costs and cost of service revenues.
For the fourth quarter, medical care cost was down 11.2% year over
year to nearly $3.8 billion.
Molina Healthcareâs interest expenses were down 27.2% year over
year to $24 million.
In the quarter under review, the company sold its Pathways
behavioral health subsidiary due to which it suffered a net loss of
$32 million.
The total membership by Government Program for 2019 stands at 3.8
billion, down 14.2% year over year.
Molina Healthcare, Inc Price, Consensus and EPS Surprise
Molina Healthcare, Inc Price, Consensus and EPS Surprise | Molina Healthcare, Inc Quote
Financial Update
As of Dec 31, 2018, Molina Healthcareâs cash and cash equivalents
saw a reduction of 11.3% to $2.8 billion from the level at year-end
2017.
Total assets fell 15.6% from 2017 end to $7.1 billion.
The companyâs shareholder equity improved nearly 23.2% from the
figure at year-end 2017 to $1.6 billion.
For the fourth quarter, net cash outflow from operating activities
stands at $123 million, narrower than the year-ago period's net
cash outflow of $153 million.
Full-Year Highlights
Total revenues for 2019 declined 5% to $18.9 billion. Net income
per share stands at $10.61 against the prior-year period's net loss
of $9.07.
2019 Guidance
For 2019, the company expects its premium revenues to be $15.8
billion.
Its total revenues are projected at $16.3 billion.
Moreover, Medicare costs are expected to be $13.7 billion. General
and administrative expenses are estimated at $1.2 billion.
Net income of the company is anticipated in the band of $600-$630
million. EBITDA is projected in the bracket of $975-$1025
million.
Net income per share is predicted to be $9.25-$9.75.
Medicaid and Medicare membership is forecast to be around 3.2
million whereas Marketplace membership is estimated to be around
250-275 million.
Zacks Rank
Molina Healthcare sports a Zacks Rank #1 (Strong Buy). You
can see the complete list of todayâs Zacks #1 Rank stocks
here.
Upcoming Releases From Medical Sector
Some other stocks worth considering from the medical sector are as
follows:
Constellation Pharmaceuticals, Inc. CNST is set to report
fourth-quarter 2018 earnings performance on Feb 14. The stock has
an Earnings ESP of +9.72% and a Zacks Rank of 1.
Tenet Healthcare Corporation THC is slated to announce
fourth-quarter earnings results on Feb 25. The company has an
Earnings ESP of +5.63% and a Zacks Rank of 3.
Alder BioPharmaceuticals, Inc. ALDR has an Earnings ESP of +13.52%
and a Zacks Rank #3 (Hold). The company is scheduled to release
fourth-quarter earnings numbers on Feb 25.
Zacks' Best Stock-Picking
Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018,
while the market gained +4.8% per year, our top stock-picking
strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the
market's +15.8% gain with a soaring +98.3% return.
Free â See the Stocks It Turned Up for Today
>>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
report
Alder BioPharmaceuticals,
Inc. (ALDR) : Free Stock Analysis Report
Molina Healthcare, Inc
(MOH) : Free Stock Analysis Report
Tenet Healthcare
Corporation (THC) : Free Stock Analysis Report
Constellation
Pharmaceuticals, Inc. (CNST) : Free Stock Analysis Report
To read this article on
Zacks.com click here.